In fact, as described in the previous section, RND1 is down-regulated in hepatocellular carcinoma, in the most aggressive subtypes of breast cancers and in glioblastoma patients, whereas it is over-expressed in esophageal squamous cell carcinoma, which could explain the contradictive effects of its variation on cell behavior. Here, RND1 is linked to glioblastoma.